SUNNYVALE, Calif., May 16, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that for the first time in Europe, at ESTRO 31, the Annual Congress of the European Society for Therapeutic Radiology and Oncology in Barcelona, Spain, the company showcased side-by-side the CyberKnife® Robotic Radiosurgery System and the TomoTherapy® System with a record 3,000 booth attendees. Additionally, during ESTRO Accuray announced and displayed the availability of the VoLO™ Planning Solution for the TomoTherapy System, a combination of a new dose calculation algorithm (NVBB – Non-Voxel Broad Beam) and a specifically designed computing hardware based on Graphics Processor Unit (GPU) technology. The VoLO Planning Solution provides intuitive, interactive plan generation, reducing significantly treatment planning time while further enhancing treatment quality.
SUNNYVALE, Calif., May 15, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the B. Riley & Company 13th Annual Investor Conference in Los Angeles on Wednesday May 23, 2012 at 11:30 a.m. PDT/2:30 p.m. EDT.
SUNNYVALE, Calif., May 9, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the availability of VoLO™ Technology for the TomoTherapy® System, a new treatment planning system that leverages advanced graphics processing technology and a new calculation algorithm to increase clinical efficiency, throughput and flexibility in developing even the most complex radiation plans.
SUNNYVALE, Calif., May 8, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today financial results for the third quarter of fiscal 2012 that ended March 31, 2012. The fiscal 2012 financial data presented below reflects Accuray’s consolidated results including the results for TomoTherapy which was acquired by Accuray in June 2011. Non-GAAP results are provided to enhance understanding of Accuray’s ongoing core results of operations.
SUNNYVALE, Calif., April 26, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the launch of the Prostate Advances in Comparative Evidence (PACE) Study, an international, multi-center, randomized study to compare CyberKnife® Stereotactic Body Radiation Therapy (SBRT), da Vinci assisted and manual laparoscopic surgery and conventionally fractionated intensity modulated radiation therapy (IMRT), for the treatment of localized prostate cancer. The PACE Study aims to build upon the strong foundation of published evidence for CyberKnife prostate SBRT by creating comparative evidence to support its future potential as the gold standard in the treatment of organ confined prostate cancer. This information will enable clinicians and patients to make informed treatment decisions based on the highest level of clinical evidence.
SUNNYVALE, Calif., April 9 , 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that it will report results for its third quarter of fiscal year 2012, ended March 31, 2012 on Tuesday, May 8, 2012 after the market closes.
SUNNYVALE, Calif., April 2, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that Kuopio University Hospital in Kuopio, Finland has begun treating patients with the CyberKnife® Robotic Radiosurgery System, providing Finland and the Nordic countries with the most advanced option in radiosurgery and stereotactic body radiotherapy (SBRT). The CyberKnife System allows Kuopio University to offer patients a non-invasive, personalized option for treatment of tumors throughout the body, including brain, spine, lung, prostate, liver, pancreas and breast tumors, enabling the hospital to offer treatments to a new group of patients.
SUNNYVALE, Calif., March 30, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the signing of a multi-year master research and collaboration agreement with the University of Heidelberg, a luminary research institution located in Heidelberg, Germany that contributes to the city’s top international position in therapy, research and science. Accuray and the University of Heidelberg will collaborate on cutting-edge research in radiation oncology to advance treatment technology and provide health care professionals with the most advanced tools for treating patients.
SUNNYVALE, Calif., March 22, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the release of PlanTouch™, the first commercially available, fully integrated software application in radiation oncology that allows physicians to remotely review and approve patients’ radiation treatment plans on the iPad. The PlanTouch software, developed in partnership with MIM Software Inc., Cleveland, Ohio, frees physicians using the CyberKnife® Robotic Radiosurgery System from work stations and provides them with increased collaboration, mobility, flexibility and convenience in delivering high-quality patient care. PlanTouch has received 510(k) clearance from the U.S. Food & Drug Administration (FDA).
SUNNYVALE, Calif., March 19, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that it has been awarded the 2012 Industry Excellence Award by Microsoft® as part of the Microsoft Dynamics Customer Excellence Awards program. Accuray will be honored at Convergence 2012, the premier Microsoft Dynamics user conference, on Monday, March 19, 2012 in Houston, Texas.
SUNNYVALE, Calif.; Feb. 29, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that it has received the NorthFace ScoreBoard AwardSM (NFSB Award) from Omega Management Group Corp. (Omega) in recognition of achieving excellence in customer service and support in 2011. In addition to getting exceptional ratings for customer satisfaction, Accuray is the first organization also to qualify for outstanding customer loyalty based on its Net Promoter ScoreTM (NPS) under a new NFSB-NPS methodology Omega announced on Dec. 6, 2011.
SUNNYVALE, Calif., February 27, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its president and chief executive officer, Euan S. Thomson, Ph.D., is scheduled to present at the Cowen and Company Healthcare Conference in Boston on Tuesday, March 6, 2012 at 8:00 a.m. EST/5:00 a.m. PST.
SUNNYVALE, Calif., February 27, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced installation of the CyberKnife® Robotic Radiosurgery System at the Tokyo Metropolitan Cancer and Infectious diseases Center, Komagome Hospital in Tokyo, Japan. Widely considered one of the leading cancer treatment centers in Japan, Tokyo Metropolitan Komagome Hospital will now be equipped to offer patients the latest advances in non-invasive, radiosurgery and Stereotactic Body radiation therapy (SBRT) treatments for tumors anywhere in the body. Today’s announcement brings the total number of CyberKnife Systems installed throughout Japan to 24, making it the second largest installed base of CyberKnife Systems in the world after the United States. Tokyo Metropolitan Komagome Hospital is expected to treat its first patient this spring.
SUNNYVALE, Calif., February 15, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the Citi 2012 Global Health Care Conference in New York City on Tuesday, February 28, 2012 at 11:00 a.m. EST/8:00 a.m. PST.
SUNNYVALE, Calif., February 8, 2012 - Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today financial results for the second quarter of fiscal 2012 that ended December 31, 2011. The fiscal 2012 financial data presented below reflects the consolidation of both Accuray and TomoTherapy, a company that was acquired by Accuray in June 2011. Non-GAAP results are provided to enhance understanding of Accuray's ongoing core results of operations.
SUNNYVALE, Calif., January 26, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today publication of a study demonstrating the benefits of the CyberKnife® Robotic Radiosurgery System in treating central lung tumors. Historically, the treatment of central lung tumors using gantry based Stereotactic Body Radiotherapy (SBRT) has been challenging and required a great deal of accuracy to avoid risks of damaging critical structures, such as the airway, esophagus and heart that can result in serious complications including death, leaving patients with fewer, less effective and sometimes only palliative options. This study, published in the January 2012 online issue of Radiotherapy & Oncology (commonly known as the Green Journal), demonstrated that the CyberKnife System, which leverages the Synchrony® Respiratory Tracking System and Lung Optimized Treatment to non-invasively track and correct for respiratory motion, allows clinicians to deliver lung SBRT to patients with central lung lesions with minimal toxicity, sparing surrounding healthy tissue, such as the esophagus, trachea and heart while also providing high levels of tumor control.
SUNNYVALE, Calif., January 18, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced that it will report results for its second quarter of fiscal year 2012, ended December 31, 2011 on Wednesday, February 8, 2012 after the market closes.
SUNNYVALE, Calif., January 16, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that CHRISTUS MUGUERZA Hospital Alta Especialidad in Monterrey, Mexico has starting treating patients with the CyberKnife® Robotic Radiosurgery System. CHRISTUS MUGUERZA is the first center in Mexico now offering patients the benefits of the CyberKnife System to treat tumors anywhere in the body.
SUNNYVALE, Calif., January 10, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today significant momentum in global adoption of its CyberKnife® Robotic Radiosurgery System and TomoTherapy® System, solidifying the company’s footprint in the large and growing radiation oncology market. This, along with the company’s short- and long-term growth strategy, was presented yesterday by Accuray President and Chief Executive Officer Euan Thomson, Ph.D. as part of the 30th Annual J.P. Morgan Healthcare Conference in San Francisco.
SUNNYVALE, Calif., January 9, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced publication of a study describing the clinical outcomes of prostate cancer patients treated with stereotactic body radiotherapy (SBRT) using Accuray’s CyberKnife® Robotic Radiosurgery System in a manner that uniquely mimics HDR (high dose rate) brachytherapy dosing within the prostate gland.
SUNNYVALE, Calif., January 5, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that its management is scheduled to present at the Needham Growth Conference in New York City on Thursday, January 12, 2012 at 8:40 a.m. EST/5:40 a.m. PST.